Investigational drug · Phase 2
OpRegen
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Age-Related Macular Degeneration, Geographic Atrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "OpRegen"
First trial start
2015
Apr 1, 2015
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OpRegen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Age-Related Macular Degeneration
- Geographic Atrophy
Approved drugs for the same conditions: Wet macular degeneration · Geographic atrophy · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "OpRegen" as an intervention, largest first.
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT05626114 · 60 participants (planned) · Start Mar 23, 2023 · Primary completion Mar 1, 2031
Drug: OpRegen · For: Geographic Atrophy
Sites: Beverly Hills, California; Sacramento, California; San Francisco, California · 17 sites in all
- Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular DegenerationActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02286089 · 24 participants · Start Apr 1, 2015 · Primary completion Dec 31, 2021
Drug: OpRegen · For: Age-Related Macular Degeneration
Sites: San Francisco, California; Cincinnati, Ohio; Philadelphia, Pennsylvania · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Systematic Review on Transplantation Studies of the Retinal Pigment Epithelium in Animal Models.
Koster C, Wever KE, Wagstaff EL, et al. · Int J Mol Sci 2020
- Long-Term Efficacy of GMP Grade Xeno-Free hESC-Derived RPE Cells Following Transplantation.
McGill TJ, Bohana-Kashtan O, Stoddard JW, et al. · Transl Vis Sci Technol 2017
Also in development for Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- ABBV-6628Phase 21 trial
AbbVie · Geographic Atrophy, Age-Related Macular Degeneration
- KH631Phase 21 trial
Chengdu Origen Biotechnology Co., Ltd. · Age-Related Macular Degeneration
- KH658Phase 21 trial
Chengdu Origen Biotechnology Co., Ltd. · Age-related Macular Degeneration
- SOM-401Phase 21 trial
Inflammasome Therapeutics · Geographic Atrophy, Age-Related Macular Degeneration
- VOY-101Phase 21 trial
Perceive Biotherapeutics, Inc. · Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.